CD86 +1057G/A polymorphism and susceptibility to Ewing's sarcoma: a case-control study

Area of Science:

• Genetics
• Immunology
• Oncology

Background:

• Ewing's sarcoma (ES) development involves genetic mutations, host factors, and cellular context.
• CD86 (B7-2) influences T cell responses, potentially impacting cancer susceptibility.
• The CD86 +1057G/A polymorphism (rs1129055) has been associated with various diseases.

Purpose of the Study:

• To investigate the association between the CD86 +1057G/A polymorphism and Ewing's sarcoma risk.
• To analyze the genetic susceptibility to ES in a Chinese population.

Main Methods:

• Case-control study design.
• Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) used to genotype the CD86 +1057G/A polymorphism.
• 158 ES cases and 212 healthy controls were analyzed.

Main Results:

• The CD86 +1057 AA genotype was significantly more frequent in ES patients (OR=2.12, p=0.021).
• The CD86 +1057 A allele was also significantly increased in ES patients (OR=1.41, p=0.018).
• These findings indicate a higher susceptibility to ES associated with the +1057G/A polymorphism.

Conclusions:

• The CD86 +1057G/A polymorphism is associated with an increased risk of Ewing's sarcoma.
• This genetic variation may contribute to cancer susceptibility in the studied population.